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Abstract: Mixed liposomes, obtained by coaggregation of 1,2-dioleoyl-sn-glycero-
3-phosphocholine and of the synthetic monomer containing a gadolinium complex 
([C18]
2
DTPA[Gd]) have been prepared. Liposomes externally decorated with KCCYSL 
(P6.1 peptide) sequence in its monomeric, dimeric, and tetrameric forms are studied as target-
selective delivery systems toward cancer cells overexpressing human epidermal growth factor 
receptor-2 (HER-2) receptors. Derivatization of liposomal surface with targeting peptides is 
achieved using the postmodification method: the alkyne-peptide derivative Pra-KCCYSL 
reacts, through click chemistry procedures, with a synthetic surfactant modified with 1, 2, or 
4 azido moieties previously inserted in liposome formulation. Preliminary in vitro data on 
MDA-MB-231 and BT-474 cells indicated that liposomes functionalized with P6.1 peptide in 
its tetrameric form had better binding to and uptake into BT-474 cells compared to liposomes 
decorated with monomeric or dimeric versions of the P6.1 peptide. BT-474 cells treated with 
liposomes functionalized with the tetrameric form of P6.1 showed high degree of liposome 
uptake, which was comparable with the uptake of anti-HER-2 antibodies such as Herceptin. 
Moreover, magnetic  MRI experiments have demonstrated the potential of liposomes to act 
as MRI contrast agents.
Keywords: anti-HER2 liposomes, target peptide, KCCYSL peptide, breast cancer, click 
chemistry, branched peptides
Introduction
Human epidermal growth factor receptor-2 (HER-2 or ErbB-2) is a 185 kDa trans-
membrane glycoprotein with an N-terminal extracellular ligand binding domain 
and an intracellular tyrosine kinase domain. It belongs to a family of receptors that 
includes four structurally related members: HER-1 (ErbB-1 or EGFR), HER-2, HER-3 
(ErbB-3), and HER-4 (ErbB-4).1 HER-2 plays a central role in many biological pro-
cesses mediated by EGFR family and is expressed at baseline levels in normal cells. 
Its overexpression is associated with a variety of cancers, such as breast and ovarian 
cancers (approximately 25%–30% of all reported cases), gastric cancer (6%–35%), 
and prostate cancer.2 This high incidence in many tumors, together with the extreme 
accessibility of its extracellular domain, renders HER-2 an attractive candidate for 
the development of selective anticancer drugs. The humanized monoclonal antibody 
anti-HER-2 (Herceptin or trastuzumab), which binds the extracellular ligand binding 
domain of the receptor, is actually the most successful therapy available in clinics for 
the treatment of HER-2-positive breast cancers. Unfortunately, a significant number 
of patients are resistant to the treatment initially or become resistant eventually.3
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Herceptin molecule or its fragments (Fab or ScFv) have 
been also used to decorate nanoparticles or liposomes for the 
selective delivery of anticancer drugs such as doxorubicin4 or 
paclitaxel5 to HER-2-positive tumors. Compared with large 
molecules such as antibodies and their derivatives, smaller 
peptide molecules appear to be more attractive targeting 
moieties because of their less expensive and simple produc-
tion, lack of immunogenicity, chemical stability, and flex-
ibility in the choice of conjugation procedures to the carrier’s 
surface.2 Actually, only three peptide sequences, AHNP, 
LTVSPWY, and KCCYSL (called P6.1), have been found to 
selectively recognize HER-2. The first one is an anti-HER-2 
peptide mimetic obtained by rational design by Park et al6 
and is based on the structure of Herceptin,7 whereas the other 
two peptides were derived from phage display libraries and 
chosen via affinity selection.8,9 The P6.1 peptide, derivatized 
with different metal chelators (DOTA, NOTA, CB-TE2A, 
DAP) and labeled with radionuclide metal ions (111In, 64Cu, 
99mTc), has been successfully used for in vivo imaging of 
HER-2 overexpressing tumor models.10–13 Single-positron 
emission computed tomography/computed tomography 
studies showed that radioconjugated peptides were able to 
accumulate specifically at the tumor site, with K
d
 ranging 
from 30 to 45 nM, with minimal nonspecific retention in 
other organs. This peptide sequence has also been proposed 
for the selective delivery of supramolecular carriers such 
as copolymeric micelles14 or pH-tunable liposomes15 for 
diagnostic or therapeutic applications.
Here, we report the synthesis, the structural characteriza-
tion, and the in vitro binding properties of novel, target-
selective liposome-based delivery systems. Mixed liposomes, 
composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) and the amphiphilic gadolinium complex 
(C18)
2
DTPA(Gd), were externally decorated with the P6.1 
peptide sequence. Liposomes with the dimeric or tetrameric 
form of P6.1 externally were also prepared and characterized 
to evaluate the effect of multimeric copies of the peptide on 
the in vitro receptor binding ability. The binding properties 
of functionalized liposomes were tested in vitro in two breast 
cancer cell lines, namely, MD-MB-231, characterized by 
low expression of HER-2, and BT-474 that overexpresses 
HER-2. Several papers have reported the capacity of peptides 
synthesized in their branched form to enhance resistance 
toward proteases and to increase linear peptide biological 
activity through multivalent binding.16–18 Recently, some 
evidence that these properties are also maintained when the 
peptide is bounded on the external liposomal surface have 
been demonstrated.19,20 Liposomes were chosen as the vector 
since they can accommodate large quantities of relevant 
therapeutic drugs in their lumen. Moreover, the addition 
of a large amount of the amphiphilic gadolinium complex 
(C18)
2
DTPA(Gd) to the liposomal formulation allows its use 
a potential contrast agent for magnetic resonance imaging 
(MRI). Our preliminary results demonstrate the binding and 
the uptake of liposomes exposing the tetrameric form of P6.1 
on BT-474 cells and also demonstrate their in vitro and in 
vivo contrast agent properties in MRI; these two features 
make the described delivery system an appealing candidate 
for future investigation so as to develop a target-selective 
theranostic agent.
Materials and instrumentation
Fmoc-protected amino acid derivatives, coupling reagents, and 
Rink amide 4-methylbenzhydrylamine (MBHA) resin were 
purchased from Calbiochem-Novabiochem (Laufelfingen, 
Switzerland). Fmoc-l-propargylglycine (Fmoc-Pra-OH) was 
bought from Neosystem (Strasbourg, France). The 14-azido-
5-oxo-3,9,12-trioxa-6-azatetradecan-1-oic acid (N
3
-Peg(9)-
COOH) was bought from Iris Biotech GmbH (Marktredwitz, 
Germany), and diethylenetriamine-N,N,N″,N″-tetra-tert-
butyl acetate-N′-acetic acid [DTPA(OtBu)
4
] was bought 
from CheMatech (Dijon, France). DOPC and 1,2-dioleoyl- 
sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine 
B sulfonyl) (Rho-PE) were purchased from Avanti Polar Lip-
ids (Alabaster, AL, USA). N,N-dioctadecylsuccinamic acid 
was synthesized according to the manufacturer’s instruction.21 
Sephadex G-50 columns were purchased from GE Health-
care Europe GmbH (Milan, Italy). All other chemicals were 
purchased from Sigma-Aldrich (St Louis, MO, USA), Fluka 
(Buchs, Switzerland), or LabScan (Stillorgan, Dublin, Ireland) 
and were used as received, unless otherwise stated. Preparative 
high-performance liquid chromatography (HPLC) was carried 
out on an LC8 Shimadzu HPLC system (Shimadzu Corpora-
tion, Kyoto, Japan) equipped with a ultraviolet lambda-Max 
Model 481 detector. For the P6.1 peptide, a Phenomenex 
(Torrance, CA, USA) C18 (300 Å, 250×21.20 mm, 5 µ) col-
umn eluted with H
2
O/0.1% trifluoroacetic acid (TFA) (A) and 
CH
3
CN/0.1% TFA (B) from 5% to 70% over 20 min at a flow 
rate of 20 mL min-1, while for all the surfactant scaffolds, a 
Phenomenex C4 (300 Å, 250×21.20 mm, 5 µ) column eluted 
with H
2
O/0.1% TFA (A) and CH
3
CN/0.1% TFA (B) from 
20% to 95% over 20 min at 20 mL min-1 flow rate was used. 
Purity and identity of the products were assessed by analytical 
liquid chromatography/mass spectrometry (LC/MS) analyses 
by using Finnigan Surveyor MSQ single quadrupole electro-
spray ionization (Finnigan; Thermo Electron Corporation, 
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San Jose, CA, USA), column: C18-Phenomenex eluted with 
H
2
O/0.1% TFA (A) and CH
3
CN/0.1% TFA (B) from 5% to 
70% over 30 min for P6.1 peptide, C4-Phenomenex eluted 
with H
2
O/0.1% TFA (A) and CH
3
CN/0.1% TFA (B) from 
20% to 95% over 20 min, both at a flow rate of 0.8 mL min-1. 
Ultraviolet–visible measurements were performed on a Nano-
Drop 2000c spectrophotometer (Thermo Fisher Scientific Inc; 
Wilmington, DE, USA) equipped with a 1.0 cm quartz cuvette 
(Hellma, Müllheim, Germany).
solid-phase synthesis
synthesis of the P6.1-alkyne peptide derivative
Pra-Lys-Cys-Cys-Tyr-Ser-Leu-NH
2
 (Pra-P6.1), schematically 
presented in Figure 1, was synthesized in solid phase under 
standard conditions by using the Fmoc/tBu strategy. Rink 
amide MBHA resin (0.73 mmol g-1, 0.1 mmol, 0.140 g) was 
used as a polymeric support. Fmoc-protected amino acids 
(4 equivalent relative to resin loading) were coupled accord-
ing to the benzotriazol-1-yl-oxy-tris-pyrrolidinophosphonium 
(PyBop)/1-hydroxybenzotriazole (HOBt)/N,N-diisopropyl-
ethylamine (DIPEA) method. In brief, Fmoc amino acid 
(4 equivalent), PyBOP (4 equivalent), HOBt (4 equivalent), 
and DIPEA (8 equivalent) were dissolved in DMF and added to 
the resin. The Fmoc protecting group was removed with 30% 
piperidine in DMF (v/v), and all couplings were performed 
twice for 1 h. Fmoc-Pra-OH was coupled once for 45 min with 
2 equivalents of PyBop/HOBt and 4 equivalents of DIPEA. 
The Fmoc protecting group on the N-terminus of propargyl-
glycine was removed by washing the resin five times with 
40% piperidine and 2% 1,8-diazabicyclo[5.4.0]undec-7-ene 
in DMF (v/v) for 10 min. At the end of the synthesis, the 
peptide was fully deprotected and cleaved from the resin with 
a cleavage cocktail containing TFA (94%), triisopropylsilane 
(TIS, 1%), ethanedithiol (EDT, 2.5%), and water (2.5%) as 
scavengers at room temperature for 2 h; then, it was precipi-
tated with ice-cold ethyl ether, filtered, dissolved in water, 
and lyophilized. The crude alkyne derivative was purified by 
reverse-phase HPLC (RP-HPLC). The final product yield was 
65%, and it was analyzed by LC/MS.
Pra-P6.1: MS (ESI+): Rt =11.21 min, m/z (%) calcd for 
C
35
H
52
N
9
O
9
S
2
 [M + H+]:806.9 amu; found: 808.0 uma.
synthesis of the surfactant scaffolds
synthesis of (c18)2-KN3 {[azide-Peg9-lys[c(O)
ch2ch2c(O)N-(c18h37)2]-amide}
(C18)
2
-KN
3
 mono-azido amphiphilic derivative, schemati-
cally depicted in Figure 1B, was synthesized according to 
experimental procedures reported previously.22
synthesis of (c18)2-K2N3 {(azide-Peg9)2-lys-lys[c(O)
ch2ch2c(O)N-(c18h37)2]-amide} and (c18)2-K4N3, 
{[(azide-Peg9)2-lys]2-lys-lys[c(O)ch2ch2c(O)
N-(c18h37)2]-amide}
(C18)
2
-K2N
3
 and (C18)
2
-K4N
3
 di- and tetra-azido amphiphilic 
derivatives, presented in Figure 1C and 1D, were synthe-
sized (Scheme 1) according to the standard procedures 
described in the “Solid-phase synthesis” section for Pra-
P6.1 peptide. The Rink amide MBHA resin (substitution 
0.73 mmol g-1, scale 0.2 mmol, 0.280 g) was used as the 
solid-phase support. After Fmoc removal from the resin 
and the coupling of Fmoc-Lys(Mtt)-OH, the resin was 
washed four times with dichloromethane (DCM), and then 
the 4-methyltrityl (Mtt) protecting group on the Nε-amino 
functional group of lysine was removed by treatment with 
DCM-TIS-TFA (94/5/1, v/v/v, 5.0 mL) for 2 min. This pro-
cedure was repeated several times until the solution became 
colorless. Then, the resin was washed three times with DCM 
and three times with DMF, and N,N-dioctadecylsuccinamic 
acid (0.249 g, 0.4 mmol) was coupled according to the pre-
viously published procedure.23 The Fmoc-Lys(Fmoc)-OH 
residue was coupled successively on the principal chain. 
The two Fmoc protecting groups, on the Nα and Nε, were 
then simultaneously removed by washing the resin five 
times with 30% piperidine in DMF (v/v) for 10 min. 
Then, the peptide-resin was split in two reactors (each one 
containing 0.1 mmol of peptide-resin), and the synthesis 
was manually completed. For the synthesis of the dimeric 
scaffold (C18)
2
-K
2
N
3
, N
3
-Peg(9)-COOH was coupled 
with DMF overnight using two equivalents of the azido-
PEGylated derivative for each NH
2
 group. For the synthesis 
of the tetrameric scaffold (C18)
2
-K4N
3
, the peptide chain 
was further elongated by coupling another lysine residue 
both on the α and the ε amino groups; then, the scaffold 
was completed by coupling two azido-PEGylated moieties 
for each N-terminal lysine. At the end of the synthesis, 
the scaffolds were cleaved from the resin using a TFA/
TIS/DTT/H
2
O mixture (92.5/2.5/2.5/2.5, v/v/v/v) at room 
temperature for 2 h, followed by precipitation with ice-cold 
water. The sample was then filtered, suspended in water, 
and lyophilized.
(C18)
2
-K2N
3
: 1H NMR (400 MHz, CDCl
3
/CD
3
OD 
50:50): d=4.43 (m, 1H; CH Lysα), 4.38 (m, 1H; CH Lysα), 
4.1 (m, 8H; OCH
2
CONH, OCH
2
CONH), 3.70 (s, 56H; 
OCH
2
CH
2
O), 3.4 (m, 8H; N
3
CH
2
CH
2
O, NHCH
2
CH
2
O), 
3.25–3.20 (m, 4H; NCH
2
), 3.24 (t, 4H; CH
2
Lysε), 3.22 (t, 4H; 
N
3
CH
2
CH
2
O), 2.64–2.49 (m, 4H; NHCOCH
2
CH
2
CO), 1.71 
(m, 4H; CH
2
Lysβ), 1.57 (m, 4H; CH
2
Lysδ),1.49 (m, 4H; 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
7.
27
.1
94
.9
2 
on
 0
3-
Fe
b-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
504
ringhieri et al
Figure 1 schematic representation of the synthetic monomers employed for liposomes formulation and surface decoration: monomeric (c18)2-KN3 (A), dimeric (c18)2-
K2N3 (B), and tetrameric scaffolds (c18)2-K4N3 (C). Pra-P6.1 peptide derivative (D) and amphiphilic gadolinium complex (c18)2DTPa(gd) (E).
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2
 
aliphatic), 0.88 ppm (t, 6H; CH
3
); MS (ESI+): m/z (%) calcd 
for C
96
H
184
N
14
O
26
 [M + H+]:1950.5; found: [M + H+]: 1951.7; 
[M + 2H+]/2: 976.4.
(C18)
2
-K4N
3
: 1H NMR (400 MHz, CDCl
3
/CD
3
OD 50:50): 
d=4.40 (m, 4H; CH Lysα), 4.1 (m, 16H; OCH
2
CONH, 
OCH
2
CONH), 3.70 (s, 112H; OCH
2
CH
2
O), 3.4 (m, 16H; 
N
3
CH
2
CH
2
O, NHCH
2
CH
2
O), 3.25–3.20 (m, 4H; NCH
2
), 3.24 
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liposome derivatized with P6.1 for her-2-overexpressing tumor cells
Scheme 1 scheme for the solid-phase synthesis of (c18)2-K2N3 (route a) and (c18)2-K4N3 (route B) monomers.
Note: The rink amide resin is schematically represented with an empty circle.
Abbreviations: Fmoc, 9-fluorenylmethoxycarbonyl; Pip, piperidine; Mtt, 4-methyltrityl; HOBt, 1-hydroxybenzotriazole; PyBop, benzotriazole-1-yl-oxy trispyrrolidinophosphonium 
hexafluorophosphonate; DIPEA, N,N-diisopropylethylamine; TIS, triisopropylsilane; TFA, trifluoroacetic acid; DTT, dithiothreitol.
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(t, 8H; CH
2
Lysε), 3.22 (t, 8H; N
3
CH
2
CH
2
O), 2.64-2.49 (m, 4H; 
NHCOCH
2
CH
2
CO), 1.71 (m, 8H; CH
2
Lysβ), 1.57 (m, 8H; 
CH
2
Lysδ),1.49 (m, 8H; CH
2
Lysγ), 1.40 (m, 4H; RCH
2
CH
3
), 
1.26 (m, 60H; CH
2
 aliphatic), 0.88 ppm (t, 6H; CH
3
); MS 
(ESI+): m/z (%) calcd for C
152
H
288
N
26
O
50
 [M + H+]:3279.7; found: 
[M + 2H+]/2: 1641.3; [M + 3H+]/3: 1094.5.
synthesis of (c18)2DTPa(gd) {(c18h37)2NcO(ch2)2 
cOlys[DTPa(gd)]cO-Nh2} amphiphilic gadolinium 
complex
The synthesis and the complexation with Gd(III) ions 
were performed according to the previously described 
procedure.24
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liposome preparation
All liposomal solutions (nonfunctionalized liposomes 
[Lipo-NT], monomeric [Lipo-M], dimeric [Lipo-D], and 
tetrameric [Lipo-T]) were prepared in 100 mM phosphate 
buffer at pH 7.4 with 0.9% wt NaCl by the thin film method.25 
Briefly, the amphiphiles were dissolved in 2 mL of a MeOH/
CHCl
3
 (50/50, v/v) mixture, and then the organic solvents 
were discarded under a gentle stream of N
2
 to obtain a thin 
film. The relative amount of each surfactant (expressed in 
mol%) used in the film preparation is reported in Table 1. 
The film was rehydrated in the phosphate buffer at 4 mM 
total lipid concentration, and the resulting suspension was 
sonicated for 30 min to allow liposome formation. Subse-
quently, all the liposomes were extruded 10 times at room 
temperature using a thermobarrel extruder system (Northern 
Lipids Inc., Vancouver, BC, Canada) under nitrogen through 
a polycarbonate membrane (Nucleopore Track Membrane 
25 mm, Whatman, Brentford, UK) with 0.1 µm pore size. 
Liposomes labeled with rhodamine were prepared by adding 
1% mol of Rho-PE to the phospholipid mixture during the 
lipid film preparation phase.
‘‘click’’ chemistry reaction on liposomes
Lipo-M, Lipo-D, and Lipo-T were externally functionalized 
with several copies of P6.1 peptide using the click chemistry 
reaction. For the reaction, 1 equivalent of the peptide deriva-
tive Pra-P6.1, 2 equivalents of sodium l-ascorbate, and 0.5 
equivalent of CuCl
2
 with respect to the azido moiety were 
added to each liposomal suspension in the exact order reported. 
The reaction mixture was stirred at 40°C for 30 min and then 
left overnight at room temperature. Unreacted peptide and 
copper ions were removed by gel-filtration chromatography 
using a Sephadex G-50 column pre-equilibrated with 100 mM 
phosphate buffer at pH 7.4 with 0.9% wt NaCl. The amount 
of peptide effectively linked to the liposomal surface was esti-
mated indirectly from the concentration of free Pra-P6.1 eluted 
from the column by using an RP-HPLC calibration curve. 
The percentage of functionalization was calculated as the ratio 
of bound P6.1 to the total amount used for the reaction.
Dynamic light scattering characterization
Liposomes were characterized by dynamic light scattering 
(DLS using a Zetasizer Nano ZS (Malvern Instruments, 
Westborough, MA, USA) equipped with a noninvasive 
backscatter system that allows measurements with a 173° 
backscatter angle. Settings for the determination of the mean 
diameter and polydispersity index (PI) of all the liposomal 
suspensions were as follows: measurement position (mm): 
4.65; attenuator: 8; temperature: 25°C; cell: disposable 
sizing cuvette. DLS samples were prepared at 2.0×10-4 M 
concentration and centrifuged at room temperature at 13,000 
rpm for 5 min. For each batch, hydrodynamic radius and size 
distribution were taken as the mean of three measurements, 
and the final values were calculated as the mean of three 
different batches.
cells
Human breast cancer cell lines MDA-MB-231 and BT-474 
were purchased from American Type Culture Collection 
(ATCC, Rockville, MD, USA). Cells were maintained at 
37°C in a humidified atmosphere containing 5% CO
2
 and 
90% of humidity; cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS; Invitrogen, NY, USA) and antibiotics 
(0.1 mg mL-1 streptomycin and 100 units mL-1 penicillin G, 
Sigma-Aldrich). HER-2 expression on MDA-MB-231 and 
BT-474 cells was assessed by flow cytometry.
In vitro viability assay
Viability of the MDA-MB-231 and BT-474 cancer cells 
was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) test. Cells were plated 
at a density of 5×103 cells per well in 96-well plates and 
incubated at 37°C in a mixture of air and 5% CO
2
. After 24 h, 
the medium was replaced with fresh medium containing 0.02, 
0.04, and 0.1 mM of sterilized liposomes, which correspond 
to a Gd-complex concentration of 0.002, 0.004, and 0.01 mM, 
respectively. After 1, 3, and 6 h of incubation, 100 µL of MTT 
solution (at 5 mg mL-1 concentration, Sigma, Italy) was added 
to each well; the plates were then incubated for an additional 
4 h (37°C, 5% CO
2
). Afterward, the formazan crystals were 
dissolved in 100 µL of dimethyl sulfoxide (DMSO) (Sigma, 
Italy). The multiwell plate was placed into a monochromator 
(ChroMate Awareness Technology) for the measurement 
of absorbance at 570 and 630 nm. Three measurements of 
Table 1 composition (mol/mol percentage) of liposomes
Systems DOPC (C18)2- 
DTPA(Gd)
(C18)2- 
KN3
(C18)2- 
K2N3
(C18)2- 
K4N3
lipo-NT 90 10 – – –
lipo-M 85 10 5 – –
lipo-D 85 10 5 –
lipo-T 85 10 – – 5
Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; Lipo-NT, non-
functionalized liposomes;  Lipo-M, monomeric liposomes; Lipo-D, dimeric liposomes; 
lipo-T, tetrameric liposomes.
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optical density (OD) were recorded for each sample, and cell 
viability (CV)% was calculated using the following equation: 
CV% = (OD
sample
/OD
control
) ×100.
In vitro binding assay
BT-474 and MDA-MB-231 cell lines were detached from cul-
ture flasks using 1% trypsin for 5 min and harvested in 15 mL 
sterile conic tubes. Then, they were pelleted, counted, and 
suspended in sterile phosphate-buffered saline (PBS). Then, 
cell lines were treated with liposomes ([Gd-complex] =0, 
0.002, 0.004, 0.01, 0.02, 0.2, 0.5 mM) functionalized with 
monomeric, dimeric, and tetrameric forms of P6.1 and labeled 
with rhodamine. Incubation conditions were 4°C for 60 min so 
as to evaluate liposome binding to cell surface while avoiding 
their internalization. After incubation, the binding capabil-
ity of liposomes was determined using a flow cytometer 
BD FACSCanto II (BD Biosciences, San Jose, CA, USA), 
equipped with three different lasers. For this experiment, the 
excitation wavelength was set at 488 nm and the emission 
wavelength at 550–570 nm, based on the fluorescence proper-
ties of rhodamine. Lipo-NT were used as the control.
In vitro uptake assay
BT-474 and MDA-MB-231 cell lines, cultured in adhesion, 
cells were seeded in 24-well plates and treated at 37°C with 
0.04 mM liposomes ([Gd-DOTA] =0.004 mM) functional-
ized with the tetrameric forms of P6.1 and labeled with 
rhodamine. Cells were monitored at different time points: 0, 
15, 30, 45, and 90 min. The specificity of uptake was deter-
mined by flow cytometry performed using a BD FACSCanto 
II apparatus with excitation and emission wavelengths at 
488 and 550–570 nm, respectively. The same cancer cells 
incubated with anti-Herceptin fluorescein isothiocyanate 
(FITC)-labeled antibody were used as positive control.
MrI
The efficiency of liposomes functionalized with the tetrameric 
forms of P6.1 to act as MRI contrast agents was evaluated by 
in vitro relaxivity measurements and in vivo imaging studies. 
For in vitro relaxivity measurements, longitudinal and 
transversal nuclear relaxation times, T
1
 and T
2
, respectively, 
were measured as a function of the Gd(III) concentration in 
aqueous solutions at 4.7 T (200 MHz) using a Bruker MRI 
tomograph (Bruker Biospin, Rheinstetten, Germany). Briefly, 
5 samples containing different Gd(III) concentrations (1, 0.5, 
0.25, 0.125, and 0.0625 mM) were prepared in water. T
1
 and 
T
2
 relaxation times were measured by using a rapid acquisi-
tion with relaxation enhancement (RARE) image sequence 
with variable relaxation time (RAREVTR). Images were 
acquired with 8 echoes (echo times ranging between 9.5 and 
76 ms) and 15 relaxation times (ranging between 241 and 
5,000 ms). Three slices with 2 mm slice thickness, field of 
view (FOV) =5×5 cm2, and 64×64 matrix size were acquired. 
To obtain quantitative relaxivity values, the longitudinal and 
transversal relaxation rates (1/T
i
) were plotted as a function 
of Gd-concentration according to the relationship:26
 1/T
imeas
 =1/T
iwater
 + r
i
 × C
Gd
, 
where i=1, 2; T
imeas
 indicates the relaxation time measured; 
T
iwater
 indicates the relaxation time of plain water; r
i
 denotes 
the relaxivity; and C
Gd
 indicates the millimolar concentration 
of Gd. The longitudinal and transversal relaxivities were 
calculated by linear best-fitting of these reported relationships 
to experimental data.
In vivo MR images were acquired using 5 mice (C57BL/6 
male mice; Harlan Laboratories, Indianapolis, IN, USA) 
that were intravenously injected with liposomes at a dose 
corresponding to 100 µmol kg-1 of Gd. Animal handling 
was performed according to the protocols approved by the 
Animal Care and Use Committee of the University of Verona 
(CIRSAL) and by the Italian Ministry of Health, in strict 
adherence to the European Communities Council (86/609/
EEC) directives. Images were acquired using a T1-weighted 
RARE sequence with TR =300 ms, TE =10.7 ms, RARE 
factor =4, slice thickness =1 mm, interslice distance =4 mm, 
FOV =6×3 cm2, and matrix size 256×128. Images were 
acquired at different time points (up to 30 min) after injec-
tion of liposomes.
Results and discussion
Design and synthesis
Many synthetic strategies for the derivatization of lipo-
somal surface with targeting synthetic peptides have been 
proposed until now.27 Peptide sequences can be introduced 
directly during liposome formulation using a peptide 
amphiphile (PA) or by grafting the liposomal surface after 
the preparation with a method well-known in literature as 
the postliposomal modification method.27 This last method 
is particularly appealing for functionalization of liposomes 
with peptides in their dimeric or multimeric form.22 The 
anchorage of multimeric copies of the peptide on the lipo-
somes can be achieved using activated functional groups 
available on the peripheral side of the liposome for covalent 
or noncovalent binding of the peptide. Many couples of 
functional groups (such as maleimide/thiol, biotin/avidin, 
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triphosphines/azides, and azides/alkyn) have been proposed 
to achieve a specific reaction. Cu(I)-catalyzed Huisgen 
cycloaddition (CuAAC), also known as “click-chemistry” 
reaction, is particularly appealing because of its regiospeci-
ficity, chemoselectivity, and orthogonality to a wide variety 
of other functional groups. In our synthesis, DOPC-based 
liposomes were doped with a low amount (5 mol%) of an 
amphiphilic monomer such as (C18)
2
-KN
3
, (C18)
2
-K2N
3
, 
or (C18)
2
-K4N
3
, as reported in Figure 1A–C. These mono-
mers contain one, two, or four PEGylated azido groups, 
respectively. Liposomes prepared with M, D, and T azido 
derivatives are here schematically indicated as Lipo-M, 
Lipo-D, and Lipo-T, respectively. Derivatization of the lipo-
somal surface with targeted P6.1 peptide was achieved by 
using Pra-P6.1 derivative (Figure 1D) in which the peptide 
moiety contains a propargylglycine at the N-terminus. All 
the reactants [Pra-P6.1, (C18)
2
-KN
3
, (C18)
2
-K2N
3
, (C18)
2
-
K4N
3
, and (C18)
2
-DTPA(Gd)], schematized in Figure 1, 
were synthesized on Rink amide resin by SPPS with Fmoc/
tBu chemistry according to the standard protocols. Chemical 
synthesis of dimeric and tetrameric azido scaffolds, (C18)
2
-
K2N
3
 and (C18)
2
-K4N
3
, was performed according to the 
reaction depicted in Scheme 1.
liposome formulation and 
characterization
Mixed liposomes DOPC/(C18)
2
-DTPA(Gd) (90/10 mol/
mol) and the analogs containing 5 mol% of PEGylated 
azido monomers (Table 1 shows the molar composition of 
the aggregates) were obtained according to the standard thin 
lipid film procedure in which the amphiphiles are dissolved 
in a mixture of organic solvents and are then removed under 
a N
2
 stream. Then, the film was hydrated by addition of 0.1 M 
phosphate buffer 0.9% wt NaCl at pH 7.4, sonicated, and 
extruded through a polycarbonate membrane with 100 nm 
pore size. The real number of functional azido groups, 
exposed on the liposomal surface, was checked using a fluo-
rescent derivative (7-nitrobenzofurazan-propargylglycine) 
as previously described by Tarallo et al.28 As expected, 
~50% of the theoretical azido groups were available on the 
outer liposomal surface for the click-chemistry reaction. 
One, two, or four copies of P6.1 peptide were bound on the 
monomeric, dimeric, or tetrameric azido scaffold to obtain 
Lipo-M6, Lipo-D6, and Lipo-T6 liposomes (Figure 2). After 
the click-chemistry reaction, liposomes were purified from 
unreacted alkyne peptide molecules and copper ions by gel-
filtration chromatography. The effective yield of the reaction 
(95% after 12 h at room temperature) was calculated using 
the RP-HPLC calibration curve as the ratio of unreacted 
P6.1-alkyne to its starting amount. The mean diameters, the 
diffusion coefficients (D), and the PIs of all the liposomal 
formulations, before and after the click-chemistry reaction, 
were assessed by DLS. The nontargeted formulation (NT 
in Figure 2) has also been prepared and characterized. Dis-
tribution functions of liposomes are reported in Figure 3, 
and their structural data are summarized in Table 2. All 
aggregate solutions present a monomodal distribution due to 
a translational diffusion process, which could be attributed 
to liposome aggregates. According to the literature, the size 
of mixed liposomes DOPC/(C18)
2
-DTPA(Gd), at 90/10 
molar ratio, was not substantially different from the size 
of pure DOPC liposomes, indicating that the insertion of a 
small amount of the amphiphilic gadolinium complex in the 
lipid mixture does not significantly influence the size of the 
DOPC liposomes29 (data not shown). Further introduction 
of (C18)
2
-KN
3
 or (C18)
2
-K2N
3
 PEGylated azido-function in 
Lipo-NT did not produce substantial deviation in the diam-
eter values (Figure 3 and Table 1). On the other hand, the 
introduction of the more hindered (C18)
2
-K4N
3
 amphiphilic 
monomer caused a slight increase in the liposomal size 
(~10%). After the click-chemistry reaction, distribution 
functions of all liposomes showed an increase of the mean 
diameter (Figure 3) of 15%, 25%, and 35% for Lipo-M6, 
Lipo-D6, and Lipo-T6, respectively.
Viability test
In vitro cell viability was assessed after incubation of BT-474 
and MDA-MB-231 cancer cells with sterilized liposomes at 
three concentrations (0.002, 0.004, and 0.01 mM) and for 
different time periods (1, 3, and 6 h). Data are reported in 
Figure 4 and show that all the investigated liposome batches 
did not cause statistically significant effect on cell viability 
on both cell lines, thus indicating the absence of toxicity.
Figure 2 schematic representation of the three targeted liposomal formulations 
(M6, D6, and T6) obtained after click-chemistry reaction.
Note: NT liposomes are also reported.
Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; NT, nontargeted.
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Figure 3 Dls plots of liposomes decorated with monomeric (A), dimeric (B), and 
tetrameric (C) forms of the P6.1 peptide at 25°c.
Notes: For each formulation, size distribution before (Lipo-M, Lipo-D, and 
Lipo-T; continuous line) and after (Lipo-M6, Lipo-D6, and Lipo-T6; dotted line) the 
functionalization with P6.1 peptide is reported.
Abbreviations: Lipo-M, monomeric liposomes; Lipo-D, dimeric liposomes; Lipo-T, 
tetrameric liposomes; DLS, dynamic light scattering.
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Table 2 structural parameters (hydrodynamic diameters, PI, and 
diffusion coefficients [D]) from DLS measurements of liposomes 
before and after reaction with P6.1 peptide
Liposomal  
systems
Diameter  
(nm) ±SD
PI D [m2 s-1] 
×10-12
lipo-NT 98±49 0.231 5.0±2.5
lipo-M 101±46 0.128 4.9±2.2
lipo-M6 118±52 0.142 4.2±1.8
lipo-D 97±47 0.152 5.1±2.5
lipo-D6 131±60 0.134 3.8±1.7
lipo-T 110±52 0.180 4.5±2.1
lipo-T6 164±90 0.234 3.0±1.6
Abbreviations: PI, polydispersity index; DLS, dynamic light scattering; SD, standard 
deviation; Lipo-NT, nonfunctionalized liposomes; Lipo-M, monomeric liposomes; 
Lipo-D, dimeric liposomes; Lipo-T, tetrameric liposomes.
Binding assay
The expression of HER-2 in MDA-MB-231 and BT-474 cells 
was preliminarily tested by flow cytometry using an anti-
Herceptin FITC-conjugated antibody and its isotype control 
(IgG1-FITC conjugated). BT-474 cells were characterized by 
substantially higher expression (from 2.5 to 10 times higher) 
of HER-2 than MDA-MB-231 cells. The binding of targeted 
and untargeted liposomes to MDA-MB-231 and BT-474 
cell surface was studied at low temperature (4°C) to avoid 
the internalization process. Results are shown in Figure 5. 
P6.1-peptide-targeted liposomes, labeled with rhodamine 
fluorophore, showed different behaviors when incubated with 
BT-474 or MDA-MB-231 cells. Liposomes functionalized 
with the tetrameric form (Lipo-T6) of the peptide displayed 
the most efficient binding to the BT-474 cancer cell line that 
overexpresses HER-2. Other liposomes, functionalized with 
the monomeric and dimeric form of the peptide, recognized 
BT-474 cancer cells, but their fluorescence was lower. The 
Lipo-T6 fluorescence signal showed a tendency to reach a 
plateau at concentrations of gadolinium complex ranging 
between 0.004 and 0.01 mM, attributable to the specific 
binding to the target antigen; at concentrations greater than 
0.01 mM, the signal started to increase linearly, indicating a 
nonspecific binding (Figure S1). At the highest investigated 
concentrations, 0.2 and 0.5 mM, the mean fluorescence signal 
was very high and was ascribable to a nonspecific binding 
(data not shown). When the same experiment was performed 
on MDA-MB-231 cell line, the Lipo-T6 fluorescence signal 
showed a tendency toward a plateau at liposome concentra-
tions higher than that used with BT-474 cancer cells (ie, 
between 0.01 and 0.02 mM).
Uptake assay
Binding and uptake are relevant for therapeutic applications 
of liposomes. Therefore, the uptake assay was performed at 
37°C to investigate the internalization of liposomes function-
alized with the tetrameric form of the peptide. In this case, the 
mean fluorescence was determined at 37°C and at different 
time intervals of incubation. As a positive control, the same 
cell lines were incubated with an anti-HER-2 Herceptin 
monoclonal antibody labeled with FITC (Figure 6). For 
BT-474 cancer cells, the mean fluorescence was not sub-
stantially different from the mean fluorescence obtained with 
Herceptin, the monoclonal antibody currently used to detect 
HER-2 overexpressing cancer cells. Using MDA-MB-231 
cancer cells, the mean fluorescence was more than 10 times 
lower than in BT-474 cancer cells and was comparable to the 
mean fluorescence obtained with Herceptin. So, this uptake 
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assay demonstrates that liposomes functionalized with the 
tetrameric form of P6.1 have uptake properties for BT-474 
comparable with those of Herceptin. These results were also 
confirmed by fluorescence microscopy (Figure S2). 
MrI
Longitudinal and transversal relaxation rates of liposome 
solutions are reported in Figure 7 (upper panel) as a function 
of Gd concentration; longitudinal and transversal relaxivities 
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Figure 4 Viability test: MTT assay on MDA-MB-231 (upper line) and BT-474 (lower line).
Notes: Panels (A) and (C) indicate cells incubated with Lipo-NT at 0.002, 0.004, and 0.01 mM Gd concentration. Panels (B) and (D) indicate cells incubated with Lipo-T6 
functionalized with the tetrameric form of the peptide at the same gd concentration.
Abbreviations: CTRL, control; Lipo-NT, nonfunctionalized liposomes; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.
Figure 5 Binding assay: MFI of BT-474 (left panel) and MDA-MB-231 (right panel) cells incubated with Lipo-NT and liposomes functionalized with different forms of the target 
peptide (monomeric lipo-M6, dimeric-lipo-D6, and tetrameric lipo-T6).
Abbreviations: MFI, mean fluorescence intensity; Lipo-NT, nonfunctionalized liposomes.
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Figure 6 Uptake assay.
Notes: The right and left panels refer to mean fluorescence for BT-474 and MDA-MB-231 cancer cells, respectively, as a function of the incubation time; cells were incubated 
at 37°C for different time intervals with 0.004 mM Lipo-T6 or an anti-HER-2 FITC-labeled antibody.
Abbreviations: MFI, mean fluorescence intensity; HER, human epidermal growth factor; FITC, fluorescein isothiocyanate.
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Figure 7 MrI.
Notes: Panels A and B show the values of longitudinal and transversal relaxation rates of water solutions containing liposomes as a function of gd concentration. The slopes 
of the fitting straight lines provide quantitative relaxivity values. Panel C shows representative MR images of the abdominal region of mice acquired before and at 15 and 
30 min after IV administration of liposomes. Enhancement of signal intensity is pronounced in liver, kidney, and blood.
Abbreviations: MRI, magnetic resonance imaging; IV, intravenous.
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were obtained by the slope of the best fitting straight lines 
of experimental data: r
1
 =3.9 mM-1s-1 and r
2
 =27.0 mM-1s-1. 
The longitudinal relaxivity is relatively low for a Gd-based 
macromolecular contrast agent but is in agreement with 
values reported for longitudinal relaxivity in similar lipo-
somal complexes containing Gd(III) at high frequency.30,31 
Representative images of the abdominal region of mice 
acquired before and at 15 and 30 min after the injection of 
liposomes are shown in Figure 7 (lower panel). The increase 
in signal intensity due to the presence of Gd is clearly detect-
able in blood, liver, and kidneys. These MRI results, although 
preliminary, demonstrate the ability of these liposomal Gd 
complexes to be detected in vivo in MRI and pave the way 
for their use as contrast agents for MRI.
Conclusion
Mixed liposomes externally decorated with P6.1 peptide 
sequence in its monomeric, dimeric, and tetrameric forms 
have been proposed as target-selective delivery systems for 
cancer cells overexpressing HER-2 receptors.
Derivatization of liposomal surface with targeting pep-
tides was achieved using the postmodification method. The 
viability assays performed to assess the biological properties 
of these derivatized liposomes showed no toxicity effects. 
Moreover, preliminary in vitro data led us to conclude that 
liposomes functionalized with P6.1 peptide in its tetrameric 
form give better binding and uptake results in cells overex-
pressing HER-2 in comparison to vectors decorated with 
monomeric or dimeric versions of the P6.1 peptide. Finally, 
in vitro and in vivo MRI experiments demonstrated the 
potential of these liposomes to be used as contrast agents 
for MRI.
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Specific binding of Lipo-T6 to BT-474 
cells
The specific binding curve of Lipo-T6 to BT-474 cells was 
obtained by subtracting the mean fluorescence intensity 
(MFI) value of Lipo-NT from the corresponding MFI value 
of Lipo-T6; the data reported in Figure S1 clearly dem-
onstrated that Lipo-T6-specific binding reaches a plateau 
between 0.004 and 0.01 mM of liposome concentration (data 
obtained after incubation for 60 min at 4°C). The increasing 
trend in MFI value between 0.01 and 0.02 mM of Lipo-T6 
concentration is due to the nonspecific binding.
confocal microscopy analysis of lipo-T6  
uptake by BT-474 and MDA-MB-231 
cancer cells
Confocal microscopy was performed using both BT-474 
and MDA-MB-231 cell lines. Cells were incubated with 
Figure S1 Binding of lipo-T6 to BT-474 cells.
Notes: The curve ( ) represents the binding of Lipo-T6; the curve ( ) 
shows the nonspecific binding of Lipo-NT, and the curve ( ) depicts the specific 
binding of Lipo-T6 to the BT-474 HER-2 positive cells.
Abbreviations: MFI, mean fluorescence intensity; Lipo-NT, nonfunctionalized 
liposome; HER, human epidermal growth factor.
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Figure S2 Upper panels: BT-474 cancer cells display uptake of herceptin (green) 
and lipo-T6 (red). lower panels: MDa-MB-231 cancer cells display very low uptake 
of both Herceptin and Lipo-T6.
Note: Nuclei are counterstained with DAPI (blue).
Abbreviation: DaPI, 4′,6-diamidino-2-phenylindole.
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anti-CD340 (Herceptin) fluorescein isothiocyanate-conjugated 
commercial antibody or with Rhodamine-Lipo-T6 for 3 h at 
37°C and 5% CO
2
. After incubation, cells were fixed with 
10% of buffered formalin, washed three times with sterile 
phosphate-buffered saline, and mounted with 4′,6-diamidino-
2-phenylindole (DAPI) mounting medium. Cells were 
analyzed using Leica Microscope SP5 and observed at 40× 
magnification.
As clearly shown in Figure S2, both anti-Herceptin anti-
body and Lipo-T6 were taken up by BT-474 tumor cells. The 
efficiency of MDA-MB-231 cell uptake was substantially 
lower when treated with both anti-Herceptin and Lipo-T6. 
Therefore, confocal microscopy confirmed the results 
obtained with flow cytometry reported in Figure 6.
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